Skip to main content
Erschienen in: Health Services and Outcomes Research Methodology 4/2019

29.10.2019

Assessing the performance of direct and indirect utility eliciting methods in patients with colorectal cancer: EQ-5D-5L versus C-TTO

verfasst von: Mahmood Yousefi, Hossein Safari, Ali Akbari Sari, Behzad Raei, Hosein Ameri

Erschienen in: Health Services and Outcomes Research Methodology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Direct and indirect preference-based methods are two main types of utility generating methods which are being frequently used in cost-utility analysis. However, a key question is how do these two methods perform in terms of validity? The aim of this study is to assess the utilities derived from EuroQol five-dimensional 5 level (EQ-5D-5L) as an indirect method and composite time trade-off (C-TTO) as a direct method in patients with colorectal cancer (CRC). A total of 223 patients with CRC were consecutively selected from three cancer centers in Tehran between May and September 2017. The EQ-5D-5L and C-TTO methods were used to estimate utilities in patients. Wilcoxon test was performed to compare utilities between C-TTO and EQ-5D-5L. In addition, intraclass correlation coefficient (ICC) and Bland–Altman plot were used to assess the agreement between the two methods. Bootstrapping quantile regression analysis was performed for comparison coefficient. The mean values of EQ-5D-5L (0.7186 ± 0.1275) for all stages were significantly higher than the C-TTO (0.4180 ± 0.4670) values. Stage 1 had the highest utility in both C-TTO (0.8167 ± 0.2332) and EQ-5D-5L (0.8339 ± 0.0535), whereas stage 4 had the lowest utility (0.1283 ± 0.5530 and 0.6001 ± 0.1220, respectively). As well, the C-TTO underestimates the values in low level of utilities and overestimates in high level of utilities. The overall ICC between the two methods was 0.50. Our study provides some tentative results about the differences between values of EQ-5D-5L and C-TTO, but clearly more work is needed to be done on this issue.
Literatur
Zurück zum Zitat Ameri, H., Yousefi, M., Yaseri, M., Nahvijou, A., Arab, M., Akbari Sari, A.: Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients. Expert Rev. Pharmacoecon. Outcomes Res. 19(1), 1–8 (2018) Ameri, H., Yousefi, M., Yaseri, M., Nahvijou, A., Arab, M., Akbari Sari, A.: Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients. Expert Rev. Pharmacoecon. Outcomes Res. 19(1), 1–8 (2018)
Zurück zum Zitat Ameri, H., Yousefi, M., Yaseri, M., Nahvijou, A., Arab, M., Akbari, Sari A.: Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients. Expert Rev. Pharmacoecon. Outcomes Res. 19(1), 89–96 (2019b)CrossRefPubMed Ameri, H., Yousefi, M., Yaseri, M., Nahvijou, A., Arab, M., Akbari, Sari A.: Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients. Expert Rev. Pharmacoecon. Outcomes Res. 19(1), 89–96 (2019b)CrossRefPubMed
Zurück zum Zitat Badia, X., Diaz-Prieto, A., Gorriz, M., Herdman, M., Torrado, H., Farrero, E., et al.: Using the EuroQol-5D to measure changes in quality of life 12 months after discharge from an intensive care unit. Intensive Care Med. 27(12), 1901–1907 (2001)CrossRefPubMed Badia, X., Diaz-Prieto, A., Gorriz, M., Herdman, M., Torrado, H., Farrero, E., et al.: Using the EuroQol-5D to measure changes in quality of life 12 months after discharge from an intensive care unit. Intensive Care Med. 27(12), 1901–1907 (2001)CrossRefPubMed
Zurück zum Zitat Bozzani, F.M., Alavi, Y., Jofre-Bonet, M., Kuper, H.: A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma. BMC Ophthalmol. 12(1), 43 (2012)CrossRefPubMedPubMedCentral Bozzani, F.M., Alavi, Y., Jofre-Bonet, M., Kuper, H.: A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma. BMC Ophthalmol. 12(1), 43 (2012)CrossRefPubMedPubMedCentral
Zurück zum Zitat Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A.: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018)CrossRefPubMed Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A.: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018)CrossRefPubMed
Zurück zum Zitat Burström, K., Johannesson, M., Diderichsen, F.: A comparison of individual and social time trade-off values for health states in the general population. Health Policy 76(3), 359–370 (2006)CrossRefPubMed Burström, K., Johannesson, M., Diderichsen, F.: A comparison of individual and social time trade-off values for health states in the general population. Health Policy 76(3), 359–370 (2006)CrossRefPubMed
Zurück zum Zitat Golicki, D., Niewada, M., van Hout, B., Janssen, M., Pickard, A.S.: Interim EQ-5D-5L value set for Poland: first crosswalk value set in Central and Eastern Europe. Value Health Reg. Issues 4, 19–23 (2014)CrossRefPubMed Golicki, D., Niewada, M., van Hout, B., Janssen, M., Pickard, A.S.: Interim EQ-5D-5L value set for Poland: first crosswalk value set in Central and Eastern Europe. Value Health Reg. Issues 4, 19–23 (2014)CrossRefPubMed
Zurück zum Zitat Golicki, D., Niewada, M., Karlińska, A., Buczek, J., Kobayashi, A., Janssen, M., et al.: Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Qual. Life Res. 24(6), 1555–1563 (2015)CrossRefPubMed Golicki, D., Niewada, M., Karlińska, A., Buczek, J., Kobayashi, A., Janssen, M., et al.: Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Qual. Life Res. 24(6), 1555–1563 (2015)CrossRefPubMed
Zurück zum Zitat Goudarzi, R., Sari, A.A., Zeraati, H., Rashidian, A., Mohammad, K., Amini, S.: Valuation of quality weights for EuroQol 5-dimensional health states with the time trade-off method in the capital of Iran. Value Health Reg. Issues 18, 170–175 (2019)CrossRefPubMed Goudarzi, R., Sari, A.A., Zeraati, H., Rashidian, A., Mohammad, K., Amini, S.: Valuation of quality weights for EuroQol 5-dimensional health states with the time trade-off method in the capital of Iran. Value Health Reg. Issues 18, 170–175 (2019)CrossRefPubMed
Zurück zum Zitat Heintz, E., Wiréhn, A.-B., Peebo, B.B., Rosenqvist, U., Levin, L.-Å.: QALY weights for diabetic retinopathy—a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO. Value Health 15(3), 475–484 (2012)CrossRefPubMed Heintz, E., Wiréhn, A.-B., Peebo, B.B., Rosenqvist, U., Levin, L.-Å.: QALY weights for diabetic retinopathy—a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO. Value Health 15(3), 475–484 (2012)CrossRefPubMed
Zurück zum Zitat Janssen, B.M., Oppe, M., Versteegh, M.M., Stolk, E.A.: Introducing the composite time trade-off: a test of feasibility and face validity. Eur. J. Health Econ. 14(1), 5–13 (2013)CrossRefPubMedCentral Janssen, B.M., Oppe, M., Versteegh, M.M., Stolk, E.A.: Introducing the composite time trade-off: a test of feasibility and face validity. Eur. J. Health Econ. 14(1), 5–13 (2013)CrossRefPubMedCentral
Zurück zum Zitat Johnson, J.A., Coons, S.J., Ergo, A., Szava-Kovats, G.: Valuation of EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics 13(4), 421–433 (1998)CrossRefPubMed Johnson, J.A., Coons, S.J., Ergo, A., Szava-Kovats, G.: Valuation of EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics 13(4), 421–433 (1998)CrossRefPubMed
Zurück zum Zitat Kang, H.-J., Kang, E., Jo, M.-W., Park, E.-J., Yoon, S., Lee, E.-K.: The utility score of epilepsy with partial seizure measured by TTO, VAS, and EQ-5D in the general Korean population. Epilepsy Res. 108(5), 963–971 (2014)CrossRefPubMed Kang, H.-J., Kang, E., Jo, M.-W., Park, E.-J., Yoon, S., Lee, E.-K.: The utility score of epilepsy with partial seizure measured by TTO, VAS, and EQ-5D in the general Korean population. Epilepsy Res. 108(5), 963–971 (2014)CrossRefPubMed
Zurück zum Zitat Lidgren, M., Wilking, N., Jönsson, B., Rehnberg, C.: Health related quality of life in different states of breast cancer. Qual. Life Res. 16(6), 1073–1081 (2007)CrossRefPubMed Lidgren, M., Wilking, N., Jönsson, B., Rehnberg, C.: Health related quality of life in different states of breast cancer. Qual. Life Res. 16(6), 1073–1081 (2007)CrossRefPubMed
Zurück zum Zitat Luo, N., Li, M., Stolk, E.A., Devlin, N.J.: The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework. Eur. J. Health Econ. 14(1), 15–24 (2013)CrossRefPubMedCentral Luo, N., Li, M., Stolk, E.A., Devlin, N.J.: The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework. Eur. J. Health Econ. 14(1), 15–24 (2013)CrossRefPubMedCentral
Zurück zum Zitat Oppe, M., Rand-Hendriksen, K., Shah, K., Ramos-Goñi, J.M., Luo, N.: EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics 34(10), 993–1004 (2016)CrossRefPubMedPubMedCentral Oppe, M., Rand-Hendriksen, K., Shah, K., Ramos-Goñi, J.M., Luo, N.: EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics 34(10), 993–1004 (2016)CrossRefPubMedPubMedCentral
Zurück zum Zitat Peeters, Y., Stiggelbout, A.M.: Health state valuations of patients and the general public analytically compared: a meta-analytical comparison of patient and population health state utilities. Value Health 13(2), 306–309 (2010)CrossRefPubMed Peeters, Y., Stiggelbout, A.M.: Health state valuations of patients and the general public analytically compared: a meta-analytical comparison of patient and population health state utilities. Value Health 13(2), 306–309 (2010)CrossRefPubMed
Zurück zum Zitat Perez, D.J., Williams, S.M., Christensen, E.A., McGee, R.O., Campbell, A.V.: A longitudinal study of health related quality of life and utility measures in patients with advanced breast cancer. Qual. Life Res. 10(7), 587–593 (2001)CrossRefPubMed Perez, D.J., Williams, S.M., Christensen, E.A., McGee, R.O., Campbell, A.V.: A longitudinal study of health related quality of life and utility measures in patients with advanced breast cancer. Qual. Life Res. 10(7), 587–593 (2001)CrossRefPubMed
Zurück zum Zitat Polsky, D., Willke, R.J., Scott, K., Schulman, K.A., Glick, H.A.: A comparison of scoring weights for the EuroQol© derived from patients and the general public. Health Econ. 10(1), 27–37 (2001)CrossRefPubMed Polsky, D., Willke, R.J., Scott, K., Schulman, K.A., Glick, H.A.: A comparison of scoring weights for the EuroQol© derived from patients and the general public. Health Econ. 10(1), 27–37 (2001)CrossRefPubMed
Zurück zum Zitat Ratcliffe, J., Brazier, J., Palfreyman, S., Michaels, J.: A comparison of patient and population values for health states in varicose veins patients. Health Econ. 16(4), 395–405 (2007)CrossRefPubMed Ratcliffe, J., Brazier, J., Palfreyman, S., Michaels, J.: A comparison of patient and population values for health states in varicose veins patients. Health Econ. 16(4), 395–405 (2007)CrossRefPubMed
Zurück zum Zitat Round, J.: Once bitten twice shy: thinking carefully before adopting the EQ-5D-5L. PharmacoEconomics 36(6), 641–643 (2018)CrossRefPubMed Round, J.: Once bitten twice shy: thinking carefully before adopting the EQ-5D-5L. PharmacoEconomics 36(6), 641–643 (2018)CrossRefPubMed
Zurück zum Zitat Ubel, P.A., Loewenstein, G., Jepson, C.: Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual. Life Res. 12(6), 599–607 (2003)CrossRefPubMed Ubel, P.A., Loewenstein, G., Jepson, C.: Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual. Life Res. 12(6), 599–607 (2003)CrossRefPubMed
Zurück zum Zitat Van Hout, B., Janssen, M., Feng, Y.-S., Kohlmann, T., Busschbach, J., Golicki, D., et al.: Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15(5), 708–715 (2012)CrossRefPubMed Van Hout, B., Janssen, M., Feng, Y.-S., Kohlmann, T., Busschbach, J., Golicki, D., et al.: Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15(5), 708–715 (2012)CrossRefPubMed
Zurück zum Zitat van Reenen, M., Janssen, B.: EQ-5D-5L User Guide: Basic Information on How to Use the EQ-5D-5L Instrument. EuroQol Research Foundation, Rotterdam (2015) van Reenen, M., Janssen, B.: EQ-5D-5L User Guide: Basic Information on How to Use the EQ-5D-5L Instrument. EuroQol Research Foundation, Rotterdam (2015)
Zurück zum Zitat Walters, S.J., Brazier, J.E.: Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual. Life Res. 14(6), 1523–1532 (2005)CrossRefPubMed Walters, S.J., Brazier, J.E.: Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual. Life Res. 14(6), 1523–1532 (2005)CrossRefPubMed
Zurück zum Zitat Zethraeus, N., Johannesson, M.: A comparison of patient and social tariff values derived from the time trade-off method. Health Econ. 8(6), 541–545 (1999)CrossRefPubMed Zethraeus, N., Johannesson, M.: A comparison of patient and social tariff values derived from the time trade-off method. Health Econ. 8(6), 541–545 (1999)CrossRefPubMed
Metadaten
Titel
Assessing the performance of direct and indirect utility eliciting methods in patients with colorectal cancer: EQ-5D-5L versus C-TTO
verfasst von
Mahmood Yousefi
Hossein Safari
Ali Akbari Sari
Behzad Raei
Hosein Ameri
Publikationsdatum
29.10.2019
Verlag
Springer US
Erschienen in
Health Services and Outcomes Research Methodology / Ausgabe 4/2019
Print ISSN: 1387-3741
Elektronische ISSN: 1572-9400
DOI
https://doi.org/10.1007/s10742-019-00204-5